• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Vaxxim - Articles and news items

First patient treated in Phase I VXM01 glioblastoma trial

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Vaximm’s VXM01 is a oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells…


Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +